Office for Technology Commercialization
http://www.research.umn.edu/techcomm
612-624-0550

Ritonavir Analog with Anticancer Activity

Technology #z08020

Questions about this technology? Ask a Technology Manager

Download Printable PDF

Image Gallery
Categories
Researchers
David Potter, MD, PhD
Associate Professor of Medicine, Division of Hematology, Oncology and Transplantation
External Link (www.dom.umn.edu)
Managed By
Raj Udupa
Technology Licensing Officer 612-624-3966
Patent Protection

Treating Cancer with Desthiazolyl Ritonavir

US Patent 20040167139

Exhibits Anticancer Activity in Cancer Models with a Lower IC50

The desthiazolyl ritonavir, a derivative of the HIV protease inhibitor Ritonavir, down regulates tumor AKT activity. AKT is a protein kinase that is important in cellular metabolism, apoptosis, cancer cell proliferation, transcription and migration. With this derivative showing inhibitory effectiveness on AKT, the tumor cell function will deteriorate and the tumor will be compromised. These molecules offer a mechanism with a lower IC50 than competitors. The primary applications that have been studied with this molecule are breast and lung xenografts.

MN-IP Try and Buy
This technology is available under a standard license. Contact Raj Udupa for specific details.

Treating Cancer More Effectively

More effective cancer treatments with mechanisms to overcome drug resistance and lower toxic side effects are needed. Drug candidates of interest must show superior anticancer activity while being effective at equal or lower dosages. The desthiazolyl ritonavir molecules can achieve these types of results in multiple cancer models.


BENEFITS OF RITONAVIR ANALOGS THAT DISRUPT CANCER CELL ACTIVITY:

  • Desthiazolvl ritonavir, a derivative of the HIV protease inhibitor, exhibits anticancer activity by disrupting the function of tumor cells
  • Desthiazolyl ritonavir down-regulates protein kinase AKT activity in cancer cells
  • Treatment mechanism and lower IC50 than competing treatments